Pacific Biosciences of California (PACB - Free Report) reported second-quarter adjusted loss of 17 cents per share, which is in line with the Zacks Consensus Estimate. The company reported loss of 26 cents in the year-ago quarter.
Pacific Biosciences carries a Zacks Rank #2 (Buy).
The Menlo Park, CA-based manufacturer of sequencing systems posted revenues of $21.6 million, which missed the Zacks Consensus Estimate of $24 million. Revenues increased7.5% from the year-ago quarter’s tally.
Product revenues totaled $18.5 million, up11.7% from the prior-year quarter’s tally.
Meanwhile, service and other revenues came in at $3.1 million, down 12.3% year over year.
Pacific Biosciences of California, Inc. Price, Consensus and EPS Surprise
Furthermore, instrument revenues totaled $8.5 million, up from $7.1 million in the year-ago quarter.
Consumable revenues came in at $10 million, up from the year-ago quarter’s $9.5 million.
Per management, Sequel instrument bookings were impressive in the second quarter. Sequel SMRT Cell usage was up more than90%.However, RS II SMRT cell usage declined by over 50%.
By the end of the quarter under review, Pacific Biosciences had approximately 275 Sequel instruments installed worldwide and roughly 30% of those are located in China.
The growth in the business partially offset decline in the RS II Smart Cell usage.
Gross profit in the second quarter of 2018 was $8.9 million, up10.6% on a year-over-year basis.Gross margin was 41.1% of total revenues, up 120 basis points (bps) year over year.
Research and Development expenses fell 7.2% to $15.7 million in the quarter. Sales, general and administrative expenses declined 3.6% to $14.9 million. Operating expenses totaled $30.6 million, down from $32.4 million in the prior-year quarter.
Pacific Biosciences exited the second quarter on a dreary note. Product and service revenues fell on a year-over-year basis due to lower instrument revenues. However, this was partially offset by a strong Sequel performance, which witnessed record bookings in the quarter.
Constant instrument orders from BGI and China are encouraging. Furthermore, the company is well poised on expansion of SMRT Sequencing and product development activities.
On the flipside, dull performance in the service and other revenue segment stemming from lower instrument revenues is a headwind. The DNA sequencing market is rife with competition. Sales in Europe declined considerably. Also, higher operating expenses are likely to mar prospects.
Q2 Earnings of MedTech Majors at a Glance
A few other top-ranked stocks in the broader medical space, which reported solid earnings this season are Stryker Corporation (SYK - Free Report) , Intuitive Surgical, Inc (ISRG - Free Report) and Illumina, Inc (ILMN - Free Report) .
While Intuitive Surgical and Illumina sport a Zacks Rank #1 (Strong Buy), Stryker carries a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Intuitive Surgical reported adjusted earnings of $2.76 per share in the second quarter of 2018, which beat the Zacks Consensus Estimate of $2.48. Adjusted earnings improved 38% year over year.
Stryker reported second-quarter 2018 adjusted earnings per share of $1.76, beating the Zacks Consensus Estimate by 1.7%. Earnings improved 15% year over year and also exceeded the high end of the company’s guidance.
Illumina reported adjusted earnings of $1.43 per share, beating the Zacks Consensus Estimate of $1.11.
Will You Make a Fortune on the Shift to Electric Cars?
Here's another stock idea to consider. Much like petroleum 150 years ago, lithium power may soon shake the world, creating millionaires and reshaping geo-politics. Soon electric vehicles (EVs) may be cheaper than gas guzzlers. Some are already reaching 265 miles on a single charge.
With battery prices plummeting and charging stations set to multiply, one company stands out as the #1 stock to buy according to Zacks research.
It's not the one you think.
See This Ticker Free >>